Drug Profile
JTK 652
Alternative Names: JTK-652Latest Information Update: 29 Apr 2009
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Apr 2009 Final adverse events and efficacy data from a phase I trial in HCV infections presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
- 30 Jun 2008 Discontinued - Phase-I for Hepatitis C (PO)
- 31 Oct 2007 Phase-I clinical trials in Hepatitis C treatment (PO)